{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:32:12Z","timestamp":1790872332326,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004773","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T00:00:00Z","timestamp":1121817600000}}],"reference-count":37,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004773.pub2","type":"journal-article","created":{"date-parts":[[2005,7,4]],"date-time":"2005-07-04T17:18:45Z","timestamp":1120497525000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV"],"prefix":"10.1002","author":[{"given":"Larry W","family":"Chang","sequence":"first","affiliation":[{"name":"University of California, San Francisco; 50 Beale Street Suite 1200 San Francisco CA USA 94105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren T","family":"Phipps","sequence":"additional","affiliation":[{"name":"University of California, San Francisco; Department of Medicine; Box 0119, M987 University of California, San Francisco San Francisco CA USA 94143-0119"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail E","family":"Kennedy","sequence":"additional","affiliation":[{"name":"University of California, San Francisco; Global Health Sciences; 50 Beale Street Suite 1200 San Francisco CA USA 94105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Rutherford","sequence":"additional","affiliation":[{"name":"University of California, San Francisco; Global Health Sciences; 50 Beale Street Suite 1200 San Francisco CA USA 94105"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,7,20]]},"reference":[{"key":"10.1002\/14651858.CD004773.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/338154","article-title":"A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand","volume":"34","author":"Chariyalertsak","year":"2002","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1468-1293.2004.00201.x","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency","volume":"5","author":"Chetchotisakd","year":"May 2004","journal-title":"HIV Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/514744","article-title":"Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled double-blind study","volume":"28","author":"McKinsey","year":"1999","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD004773.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJM199503163321102","article-title":"A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection","volume":"332","author":"Powderly","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1468-1293.2001.00060.x","article-title":"A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection","volume":"2","author":"Smith","year":"2001","journal-title":"HIV Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004773.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00365549509019015","article-title":"Fluconazole for the primary prophylaxis of AIDS-associated cryptococcosis: a case-control study","volume":"27","author":"Ammassari","year":"1995","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/515018","article-title":"Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS","volume":"27","author":"Havlir","year":"1998","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD004773.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archinte.1997.00440220068009","article-title":"Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection","volume":"157","author":"Manfredi","year":"1997","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/00002030-199405000-00011","article-title":"The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection","volume":"8","author":"Nelson","year":"1994","journal-title":"AIDS"},{"issue":"11","key":"10.1002\/14651858.CD004773.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/00002030-199511000-00012","article-title":"Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection","volume":"9","author":"Newton","year":"1995","journal-title":"AIDS"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00002030-199202000-00008","article-title":"Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients","volume":"6","author":"Nightingale","year":"1992","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0140-6736(95)90465-4","article-title":"Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients","volume":"345","author":"Quagliarello","year":"1995","journal-title":"The Lancet"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/clinids\/23.6.1282","article-title":"Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or =100\/mm3: demonstration of efficacy in a prospective, multicenter trial","volume":"23","author":"Singh","year":"1996","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0014|cit14","unstructured":"Lalloo D Primary prevention of invasive cryptococcoal disease using fluconazole prophylaxis in Human Immunodeficiency Virus (HIV) infected Ugandans ISRCTN76481529"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0015|cit15","first-page":"http:\/\/hivinsit","article-title":"Cryptococcosis and HIV","volume-title":"HIV InSite Knowledge Base","author":"Aberg","year":"October 2002"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0016|cit16","first-page":"1","article-title":"Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents","volume":"53(RR15)","author":"Benson","journal-title":"MMWR"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/517056","article-title":"The hidden danger of primary fluconazole prophylaxis for patients with AIDS","volume":"26","author":"Berg","year":"1998","journal-title":"Clinical Infectious Disease"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/319348","article-title":"Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-98: regional variation and temporal trends","volume":"32","author":"Chariyalertsak","year":"2001","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/00002030-199817000-00013","article-title":"Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment","volume":"12","author":"Chene","year":"1998","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0020|cit20","unstructured":"Clarke M Oxman AD Cochrane Reviewers' Handbook 4.1.6 [updated January 2003]. In: The Cochrane Library, Issue 1, 2003 Update Software; Updated quarterly"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00002030-200402200-00024","article-title":"Epidemiology of HIV-associated cryptococcosis in France (1985-2002): comparison of pre- and post- HAART eras","volume":"18","author":"Dromer","year":"2004","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0022|cit22","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926","volume-title":"Systematic Reviews in Health Care: Meta-analysis in context","author":"Egger","year":"2001"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00002030-200205030-00009","article-title":"Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults","volume":"16","author":"French","year":"2002","journal-title":"AIDS"},{"issue":"4","key":"10.1002\/14651858.CD004773.pub2-BIB0024|cit24","article-title":"Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV (Cochrane Review)","author":"Grimwade","year":"2003","journal-title":"The Cochrane Library"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1086\/314606","article-title":"Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons","volume":"179","author":"Hajjeh","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1468-1293.2004.00199.x","article-title":"Primary prophylaxis for cryptococcal meningitis","volume":"5","author":"John","year":"2004","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0028|cit28","first-page":"1","article-title":"Guidelines for Preventing of Opportunistic Infections Among HIV-Infected Persons---2002","volume":"51(RR08)","author":"Kaplan","journal-title":"MMWR"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1086\/343862","article-title":"Trends in Causes of Death among Persons with Acquired Immunodeficiency Syndrome in the Era of Highly Active Antiretroviral Therapy, San Francisco, 1994-1998","volume":"186","author":"Louie","year":"2002","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1097\/00002030-199909100-00012","article-title":"Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis","volume":"13","author":"McNaghten","year":"1999","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/00002030-199814000-00013","article-title":"Opportunistic infections occurring during highly active antiretroviral treatment","volume":"12","author":"MIchelet","year":"1998","journal-title":"AIDS"},{"issue":"13","key":"10.1002\/14651858.CD004773.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/0272989X9701700402","article-title":"The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients","volume":"17","author":"Scharfstein","year":"1997","journal-title":"Medical Decision Making"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00126334-199908010-00011","article-title":"Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand","volume":"21(4)","author":"Tansuphasawadikul","year":"1999","journal-title":"Journal of Acquired Immunodeficiency Syndromes"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0035|cit35","unstructured":"Tuli K Clark T Ningsanond P Morgan J Laosiritaworn Y Kongsin S Thanprasertsuk S Tappero J Hajjeh R Primary prophylaxis against fungal infections among persons living with AIDS in Thailand: a cost-effectiveness analysis Tenth Conference on Retroviruses and Opportunistic Infections Boston Tenth Conference on Retroviruses and Opportunistic Infections"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0036|cit36","unstructured":"World Health Organization United Nations Children's Fund Joint United Nations Programme on HIV\/AIDS Medecins Sans Frontieres Sources and prices of selected medicines and diagnostics for people living with HIV\/AIDS www.who.int\/medicines 2004"},{"key":"10.1002\/14651858.CD004773.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1086\/344902","article-title":"Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis","volume":"36","author":"Yazdanpanah","year":"2003","journal-title":"Clinical Infectious Diseases"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004773.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004773.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:39:49Z","timestamp":1628545189000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004773.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane HIV\/AIDS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,7,20]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004773.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004773.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,20]]}}}